Annual SGA
$35.51 M
+$8.48 M+31.40%
December 31, 2023
Summary
- As of February 12, 2025, XFOR annual SGA is $35.51 million, with the most recent change of +$8.48 million (+31.40%) on December 31, 2023.
- During the last 3 years, XFOR annual SGA has risen by +$14.56 million (+69.54%).
- XFOR annual SGA is now at all-time high.
Performance
XFOR SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$15.66 M
+$2.38 M+17.94%
September 30, 2024
Summary
- As of February 12, 2025, XFOR quarterly SGA is $15.66 million, with the most recent change of +$2.38 million (+17.94%) on September 30, 2024.
- Over the past year, XFOR quarterly SGA has increased by +$2.38 million (+17.94%).
- XFOR quarterly SGA is now -10.18% below its all-time high of $17.43 million, reached on March 31, 2024.
Performance
XFOR Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.92 B
-$16.76 M-0.88%
September 30, 2024
Summary
- As of February 12, 2025, XFOR TTM SGA is -$1.92 billion, with the most recent change of -$16.76 million (-0.88%) on September 30, 2024.
- Over the past year, XFOR TTM SGA has dropped by -$1.97 billion (-4040.60%).
- XFOR TTM SGA is now -3191.68% below its all-time high of -$58.39 million.
Performance
XFOR TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
XFOR Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +31.4% | +17.9% | -4040.6% |
| 3 y3 years | +69.5% | +17.9% | -4040.6% |
| 5 y5 years | +306.3% | +257.3% | -10000.0% |
XFOR Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +43.7% | -10.2% | +159.1% | -95.9% | +0.1% |
| 5 y | 5-year | at high | +101.3% | -10.2% | +300.1% | -330.1% | +0.1% |
| alltime | all time | at high | +1575.5% | -10.2% | +1607.2% | -3191.7% | +0.1% |
X4 Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $15.66 M(+17.9%) | $56.30 M(+15.4%) |
| Jun 2024 | - | $13.28 M(-23.8%) | $48.77 M(+6.7%) |
| Mar 2024 | - | $17.43 M(+75.6%) | $45.70 M(+28.7%) |
| Dec 2023 | $35.51 M(+31.4%) | $9.93 M(+22.1%) | $35.51 M(+10.5%) |
| Sep 2023 | - | $8.13 M(-20.3%) | $32.14 M(+7.0%) |
| Jun 2023 | - | $10.20 M(+40.9%) | $30.05 M(+13.0%) |
| Mar 2023 | - | $7.24 M(+10.3%) | $26.60 M(-1.6%) |
| Dec 2022 | $27.02 M(+9.4%) | $6.56 M(+8.6%) | $27.02 M(-2.1%) |
| Sep 2022 | - | $6.04 M(-10.4%) | $27.59 M(+0.4%) |
| Jun 2022 | - | $6.75 M(-11.9%) | $27.48 M(+3.6%) |
| Mar 2022 | - | $7.66 M(+7.4%) | $26.53 M(+7.4%) |
| Dec 2021 | $24.70 M(+18.0%) | $7.13 M(+20.3%) | $24.70 M(+7.8%) |
| Sep 2021 | - | $5.93 M(+2.2%) | $22.92 M(+1.5%) |
| Jun 2021 | - | $5.80 M(-0.5%) | $22.59 M(+2.2%) |
| Mar 2021 | - | $5.83 M(+8.9%) | $22.10 M(+5.5%) |
| Dec 2020 | $20.94 M | $5.36 M(-4.3%) | $20.94 M(+7.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $5.60 M(+5.3%) | $19.50 M(+6.7%) |
| Jun 2020 | - | $5.32 M(+13.8%) | $18.28 M(+4.3%) |
| Mar 2020 | - | $4.67 M(+19.3%) | $17.53 M(-0.6%) |
| Dec 2019 | $17.64 M(+101.9%) | $3.91 M(-10.7%) | $17.64 M(+39.0%) |
| Sep 2019 | - | $4.38 M(-3.9%) | $12.69 M(+9.6%) |
| Jun 2019 | - | $4.56 M(-4.7%) | $11.58 M(+8.2%) |
| Mar 2019 | - | $4.78 M(-560.3%) | $10.71 M(+22.5%) |
| Dec 2018 | $8.74 M(+9.2%) | -$1.04 M(-131.7%) | $8.74 M(-28.1%) |
| Sep 2018 | - | $3.27 M(-11.2%) | $12.15 M(+7.2%) |
| Jun 2018 | - | $3.69 M(+30.8%) | $11.33 M(+20.8%) |
| Mar 2018 | - | $2.82 M(+18.6%) | $9.39 M(+17.3%) |
| Dec 2017 | $8.01 M(+22.9%) | $2.38 M(-3.2%) | $8.01 M(+12.7%) |
| Sep 2017 | - | $2.46 M(+41.3%) | $7.10 M(+52.8%) |
| Jun 2017 | - | $1.74 M(+21.0%) | $4.65 M(+59.7%) |
| Mar 2017 | - | $1.44 M(-2.5%) | $2.91 M(+97.5%) |
| Dec 2016 | $6.51 M(+207.5%) | $1.47 M | $1.47 M |
| Dec 2015 | $2.12 M | - | - |
FAQ
- What is X4 Pharmaceuticals annual SGA?
- What is the all time high annual SGA for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals annual SGA year-on-year change?
- What is X4 Pharmaceuticals quarterly SGA?
- What is the all time high quarterly SGA for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals quarterly SGA year-on-year change?
- What is X4 Pharmaceuticals TTM SGA?
- What is the all time high TTM SGA for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals TTM SGA year-on-year change?
What is X4 Pharmaceuticals annual SGA?
The current annual SGA of XFOR is $35.51 M
What is the all time high annual SGA for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high annual SGA is $35.51 M
What is X4 Pharmaceuticals annual SGA year-on-year change?
Over the past year, XFOR annual SGA has changed by +$8.48 M (+31.40%)
What is X4 Pharmaceuticals quarterly SGA?
The current quarterly SGA of XFOR is $15.66 M
What is the all time high quarterly SGA for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high quarterly SGA is $17.43 M
What is X4 Pharmaceuticals quarterly SGA year-on-year change?
Over the past year, XFOR quarterly SGA has changed by +$2.38 M (+17.94%)
What is X4 Pharmaceuticals TTM SGA?
The current TTM SGA of XFOR is -$1.92 B
What is the all time high TTM SGA for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high TTM SGA is -$58.39 M
What is X4 Pharmaceuticals TTM SGA year-on-year change?
Over the past year, XFOR TTM SGA has changed by -$1.97 B (-4040.60%)